NCT00048633View on ClinicalTrials.gov

Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

June 30, 2003

Study Completion Date

June 30, 2003

Conditions
Breast Neoplasms
Interventions
DRUG

Chemotherapy

Trial Locations (4)

47591

Medical Center of Vincennes, Vincennes

76012

Arlington Cancer Center, Arlington

32207-5905

Florida Oncology Associates, Jacksonville

77030-4009

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

QLT Inc.

INDUSTRY

NCT00048633 - Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer | Biotech Hunter | Biotech Hunter